Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 26;12:757228. doi: 10.3389/fendo.2021.757228

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Martin, Chuah, Abdelaal, Pedersen, Malmodin, Abrahamsson, Hutter, Godson, Brennan, Fändriks, le Roux and Docherty

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

In silico deconvolution of medication-specific and PPAR isotype-specific transcriptomic effects following RYGB-FMRR. (A, D) Genes responsive to FMRR medications (A) and PPAR isotypes (D) were retrieved from IPA, intersected with transcripts identified in the RYGB-FMRR versus RYGB differential expression analysis, and presented on doughnut plots with counts and percentages of transcripts in each category outlined. The inner doughnut layers outline all transcripts known to be responsive to each medication (A) or PPAR isotype (D). The outer layers stratify transcripts by presence in or absence from the RYGB-FMRR vs RYGB DEG list. (B, E) Venn diagram enumeration of the overlap and separation in transcripts present in the RYGB-FMRR vs RYGB DEG list and responsive to one or more of the FMRR medications (B) or one or more of the PPAR isotypes (E). These transcripts are labelled as ‘In DEG list’ in the outer doughnut layers in (A, D), respectively. (C, F) Subsets of genes present in the RYGB-FMRR vs RYGB DEG list and found to be responsive to FMRR medications (C) or PPAR isotypes (F) are presented on doughnut plots with counts and percentages of transcripts in each category outlined. Transcripts are stratified by fenofibrate- (C) or PPARα- (F) responsiveness (inner layers), presence or absence from Kidney Tubules Expression Atlas (KTEA; middle layers), and localisation in either the proximal tubule or the rest of the renal tubule in KTEA (outer layers). (G) Dotplots of over-represented Reactome pathways for fenofibrate- and PPARα-responsive genes present in the RYGB-FMRR vs RYGB DEG list. The size of dots is scaled by the gene ratio. DEG, differentially expressed gene; FF, fenofibrate; FMRR, fenofibrate, metformin, ramipril, and rosuvastatin; KTEA, Kidney Tubules Expression Atlas; PPAR, peroxisome proliferator-activated receptor; PPARα, peroxisome proliferator-activated receptor-alpha; PPARδ, peroxisome proliferator-activated receptor-delta; PPARγ, peroxisome proliferator-activated receptor-gamma; PT, proximal tubule; RYGB, Roux-en-Y gastric bypass; RYGB-FMRR, Roux-en-Y gastric bypass plus fenofibrate, metformin, ramipril, and rosuvastatin.